Ovarian cancer is one of most lethal diseases in female population worldwide. The standard treatment (after surgical resection) is chemotherapy based mainly on carboplatin (CBDCA) and taxane. However, the main obstacle to a better prognosis is resistance to CBDCA. The nature of this resistance is...
Enlace original:
http://repositorio.anid.cl/handle/10533/241984
